Tag Archives: AGIO

Agios Pharma (AGIO) Received its Third Buy in a Row

After Piper Jaffray and Leerink Partners gave Agios Pharma (NASDAQ: AGIO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Chris Shibutani reiterated a Buy rating on Agios Pharma today. The company’s

Oppenheimer Maintains a Hold Rating on Agios Pharma (AGIO)

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $66.83. Cann said: “The updated data for AG-881 ongoing phase I study presented today include approximately three

The CEO of Agios Pharma is Exercising Options

Today it was reported that the CEO of Agios Pharma (NASDAQ: AGIO), David Schenkein, exercised options to buy 75,119 AGIO shares at $3.31 a share, for a total transaction value of $249K. Following David Schenkein’s last AGIO Buy transaction on

Analysts Are Bullish on These Healthcare Stocks: Agios Pharma (AGIO), Tactile Systems Technology (TCMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (NASDAQ:AGIO) and Tactile Systems Technology (NASDAQ:TCMD) with bullish sentiments. Agios Pharma (AGIO) In a report released today, John Newman from

Agios Pharma (AGIO) Gets a Hold Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Agios Pharma (NASDAQ: AGIO). The company’s shares opened today at $82.38. Cann commented: “AG-881 is a promising early-stage molecule. We have not included any impact

Analysts’ Top Healthcare Picks: Agios Pharma (AGIO), Intra-Cellular Therapies (ITCI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agios Pharma (NASDAQ:AGIO), Intra-Cellular Therapies (NASDAQ:ITCI) and Adaptimmune Therapeutics (NASDAQ:ADAP) with bullish sentiments. Agios Pharma (AGIO) In a report released today, John